S&P Futures
3,730.25 -1.75 (-0.05%) Dow Futures
29,740.00 -10.00 (-0.03%) Nasdaq Futures
11,543.00 -12.75 (-0.11%) Russell 2000 Futures
1,721.10 +0.30 (+0.02%) Crude Oil
82.25 +0.10 (+0.12%) Gold
1,664.50 -5.50 (-0.33%)
Boston Properties, Inc. (BXP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 73.66 |
| Open | 74.38 |
| Bid | 73.23 x 1000 |
| Ask | 78.29 x 900 |
| Day's Range | 73.47 - 77.30 |
| 52 Week Range | 73.41 - 133.11 |
| Volume | |
| Avg. Volume | 1,285,795 |
| Market Cap | 11.99B |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | 18.21 |
| EPS (TTM) | 4.20 |
| Earnings Date | Oct 24, 2022 - Oct 28, 2022 |
| Forward Dividend & Yield | 3.92 (5.08%) |
| Ex-Dividend Date | Sep 29, 2022 |
| 1y Target Est | 98.95 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BXP
Related Research
- Boston Properties, Inc.Analyst Report: Boston Properties, Inc.Boston Properties Inc. is a real estate investment trust (REIT). The company is one of the largest owners and developers of Class A office properties in the U.S. The company's assets include offices, hotels, retail, and residences; however, about 90% of revenues are from office space. The portfolio is concentrated in large coastal cities, including Boston, Los Angeles, New York, San Francisco, and Washington, D.C. At the end of 2021, the company expanded into the Seattle market. BXP's portfolio consists of 201 properties with 53 million square feet. BXP's top 20 tenants represent about 29% of annualized rent, and have a remaining weighted-average lease term of 10.6 years. Tenant diversification is as follows: financial services/investment banking, 23%; legal, 21%; tech/media, 20%; financial services, 16%; insurance, 8%; life sciences, 7%; and retail, 6%. The shares are included in the S&P 500.RatingFair ValueEconomic Moat2 months agoArgus Research
- Zacks
Boston Properties' (BXP) Buyout Boosts Life-Science Portfolio
Boston Properties (BXP) acquires 125 Broadway in Kendall Square in Cambridge, MA, from Biogen for $592 million. The move aids its expansion efforts in the life sciences space in Cambridge.
- American City Business Journals
Biogen sells one Kendall Square building, ends lease on another
Biogen Inc. has sold a six-floor lab building in Kendall Square to Boston Properties Inc. for $603 million and ended its lease early on a nearby office building, as part of its continued drive to shrink its real estate footprint.
- Business Wire
BXP Expands Life Sciences Portfolio in Kendall Square in Cambridge, MA
BOSTON, September 20, 2022--BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, announced today that it completed the acquisition of 125 Broadway, a six-story, 271,000 square foot laboratory/life sciences property. BXP purchased the property from Biogen for a gross purchase price of approximately $592.0 million. Biogen has signed a lease for and will continue to occupy the entire property through April 2028. BXP funded the purcha
